Tags

Type your tag names separated by a space and hit enter

[Seroprevalence of hepatitis A and cost evaluation of different vaccination strategies against hepatitis A virus in patients with chronic hepatitis C in France].
Gastroenterol Clin Biol. 2002 Mar; 26(3):256-60.GC

Abstract

OBJECTIVES

To prospectively determine the prevalence of total hepatitis virus A antibodies in patients with chronic hepatitis C and to evaluate the direct costs of several vaccination strategies against hepatitis A virus in these patients.

METHODS

From April 1 to July the 31 1998, 219 patients with hepatitis C virus antibodies underwent a systematic testing for total hepatitis virus A antibodies (MEIA-AXSYM, Abbott laboratories). The prevalence of hepatitis A virus antibodies was evaluated according to age and suspected way of hepatitis C contamination. This prevalence has been compared to that in individuals undergoing a check-up provided by the national health insurance system stratified by age. Direct costs of 2 vaccination strategies "A" and "B" were evaluated according to age (<40 vs > 40 years) and number of vaccine doses (1 or 2). "A" strategy included the systematic vaccination of all patients without determining the presence of total hepatitis A antibodies. "B" strategy included testing for total hepatitis A antibodies and vaccination of seronegative patients. The costs of these two strategies (A and B) were calculated with one and two vaccine doses.

RESULTS

The prevalence of total hepatitis A antibodies was 76% in the entire population. It increased after the age of 35 and was statistically higher in patients who were older than 40 than in patients younger than 40. This prevalence was not significantly different from that in individuals who underwent a check-up provided by the national health insurance system stratified according to age. "B" strategy with 2 vaccine doses was less expensive that A strategy in the whole population and in patients younger than 40. This strategy was less expensive with 1 vaccine dose except in patients who had recently screened positive for hepatitis C antibodies younger than 40 when it induced an increased in direct cost due to the low prevalence of total hepatitis A antibodies in these patients.

CONCLUSIONS

In patients with hepatitis C antibodies with a high prevalence of total hepatitis A antibodies, testing for the prevalence of these antibodies before vaccination decreases the direct cost of this vaccination.

Authors+Show Affiliations

Cellule de Médicalisation du Système d'Information, Hôpital Beaujon, 92118 Clichy, France.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't

Language

fre

PubMed ID

11981470

Citation

Rufat, Pierre, et al. "[Seroprevalence of Hepatitis a and Cost Evaluation of Different Vaccination Strategies Against Hepatitis a Virus in Patients With Chronic Hepatitis C in France]." Gastroenterologie Clinique Et Biologique, vol. 26, no. 3, 2002, pp. 256-60.
Rufat P, Dumouchel P, Cadranel JF. [Seroprevalence of hepatitis A and cost evaluation of different vaccination strategies against hepatitis A virus in patients with chronic hepatitis C in France]. Gastroenterol Clin Biol. 2002;26(3):256-60.
Rufat, P., Dumouchel, P., & Cadranel, J. F. (2002). [Seroprevalence of hepatitis A and cost evaluation of different vaccination strategies against hepatitis A virus in patients with chronic hepatitis C in France]. Gastroenterologie Clinique Et Biologique, 26(3), 256-60.
Rufat P, Dumouchel P, Cadranel JF. [Seroprevalence of Hepatitis a and Cost Evaluation of Different Vaccination Strategies Against Hepatitis a Virus in Patients With Chronic Hepatitis C in France]. Gastroenterol Clin Biol. 2002;26(3):256-60. PubMed PMID: 11981470.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Seroprevalence of hepatitis A and cost evaluation of different vaccination strategies against hepatitis A virus in patients with chronic hepatitis C in France]. AU - Rufat,Pierre, AU - Dumouchel,Patrice, AU - Cadranel,Jean-François, PY - 2002/5/1/pubmed PY - 2002/7/10/medline PY - 2002/5/1/entrez SP - 256 EP - 60 JF - Gastroenterologie clinique et biologique JO - Gastroenterol Clin Biol VL - 26 IS - 3 N2 - OBJECTIVES: To prospectively determine the prevalence of total hepatitis virus A antibodies in patients with chronic hepatitis C and to evaluate the direct costs of several vaccination strategies against hepatitis A virus in these patients. METHODS: From April 1 to July the 31 1998, 219 patients with hepatitis C virus antibodies underwent a systematic testing for total hepatitis virus A antibodies (MEIA-AXSYM, Abbott laboratories). The prevalence of hepatitis A virus antibodies was evaluated according to age and suspected way of hepatitis C contamination. This prevalence has been compared to that in individuals undergoing a check-up provided by the national health insurance system stratified by age. Direct costs of 2 vaccination strategies "A" and "B" were evaluated according to age (<40 vs > 40 years) and number of vaccine doses (1 or 2). "A" strategy included the systematic vaccination of all patients without determining the presence of total hepatitis A antibodies. "B" strategy included testing for total hepatitis A antibodies and vaccination of seronegative patients. The costs of these two strategies (A and B) were calculated with one and two vaccine doses. RESULTS: The prevalence of total hepatitis A antibodies was 76% in the entire population. It increased after the age of 35 and was statistically higher in patients who were older than 40 than in patients younger than 40. This prevalence was not significantly different from that in individuals who underwent a check-up provided by the national health insurance system stratified according to age. "B" strategy with 2 vaccine doses was less expensive that A strategy in the whole population and in patients younger than 40. This strategy was less expensive with 1 vaccine dose except in patients who had recently screened positive for hepatitis C antibodies younger than 40 when it induced an increased in direct cost due to the low prevalence of total hepatitis A antibodies in these patients. CONCLUSIONS: In patients with hepatitis C antibodies with a high prevalence of total hepatitis A antibodies, testing for the prevalence of these antibodies before vaccination decreases the direct cost of this vaccination. SN - 0399-8320 UR - https://www.unboundmedicine.com/medline/citation/11981470/[Seroprevalence_of_hepatitis_A_and_cost_evaluation_of_different_vaccination_strategies_against_hepatitis_A_virus_in_patients_with_chronic_hepatitis_C_in_France]_ L2 - http://www.em-consulte.com/retrieve/pii/MDOI-GCB-03-2002-26-3-0399-8320-101019-ART13 DB - PRIME DP - Unbound Medicine ER -